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INTRODUCTION:  Lesser  sac  pathological  entities  are uncommon.  Most  of  these  are  tumors  and  are  gener-
ally misdiagnosed  as  retroperitoneal  lesions.
CASE REPORT:  A  62  year  old  male  with  past  history  of treated  hypopharyngeal  cancer  presented  with
progressive  abdominal  distension.  Physical  examination  revealed  a midline  intra  abdominal  mass  in
the  epigastrium  and  umbilical  region.  Radiological  investigations  were  suggestive  of  a retroperitoneal
tumor,an  image  guided  biopsy  was  reported  as  atypical  lipoma.  Surgical  exploration  conﬁrmed  a  large
multi  lobulated  tumor  arising  primarily  from  the  lesser  sac,  post  operative  histopathological  examination
conﬁrmed  a myxoid  liposarcoma.
DISCUSSION:  Primary  lesser  sac  tumors  are  rare,  a literature  review  of  primary  lesser  sac  tumors  with
particular  reference  to  myxoid  liposarcoma  is presented.
CONCLUSION:  Primary  lesser  sac  liposarcomas  are  rare neoplasms.  The  myxoid  variant  is unique  for  its
peculiar  biological  behavior,  in its sensitivity  to chemotherapy  and  radiotherapy  and  for the  presence  of
speciﬁc  cytogenetic  marker.
©  2016  The  Author(s).  Published  by Elsevier  Ltd on behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open
he CCaccess  article  under  t
. Introduction
Lipomas represent 50% of all benign soft tissue tumors. Liposar-
oma comprises of 15% of adult sarcomas and predominantly affect
he extremities [1]. About 10–20% of sarcomas arise from the
etroperitonium and includes a heterogenous list of histological
ypes [2]. The most common site for abdominal liposarcoma is the
etroperitonium. Primary lesser sac sarcomas are rare and lesions
re often misdiagnosed as originating from the retroperitonium [3].
e report this case for the rare site of origin and unusual histology.
. Case report
A 62 year old male presented with progressive distention of
he abdomen. He had completed multimodal treatment with 60 Gy
f external beam radiotherapy and 4 cycles of cisplatin and 5 FU
hemotherapy for locally advanced hypopharyngeal cancer 11
onths back. On examination he had a 20 × 10 cm midline intra
bdominal mass occupying the epigastrium,umbilicus and upper
ypogastrium. A USG abdomen revealed a large solid retroperi-
oneal mass displacing bowel loops and left kidney with bilateral
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hydrocele. MRI/CT scan showed a large 30 × 23 × 13 cm lobulated
mass in the retroperitonium with predominant intermediate sig-
nals and multifocal areas of fat intensity on T1 images (Fig. 1). A
core biopsy done before referral to our unit was reported as atyp-
ical lipoma. Further evaluation with CT chest and testicular tumor
markers were normal. An upper GI endoscopy revealed a normal
gastric mucosa with extrinsic compression along the greater cur-
vature.
A provisional diagnosis for retroperitoneal atypical
lipoma/liposarcoma was made and surgical exploration done
by a midline laparotomy incision. A large well encapsulated,
multi lobulated mass arising posterior to stomach but anterior
to pancreas and displacing left kidney, spleen and bowels was
encountered (Fig. 1). A diagnosis of lesser sac tumor was  made
and complete excision of the mass was done. Post operative
histopathological examination conﬁrmed liposarcoma−myxoid
variant (Fig. 2). IHC studies showed the tumor to be S100 and
vimentin positive (Fig. 3) but desmin negative. The patient had an
uneventful post operative period and was  discharged.
3. Discussion
Primary lesser sac pathological processess are rare. A dynamic
list of infective, inﬂammatory and neoplastic lesions affecting the
lesser sac has been reported in literature. Space-occupying lesions
of the lesser sac include pancreatic pseudocysts or abscesses, lym-
phadenopathy along the lesser curvature of the stomach, and
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Fig. 1. CT scan & intra operative photograph showing tumor (arrow) posterior to stomach (cross) but anterior to pancreas (star), kidneys and vessels.
Fig. 2. Showing bimorphic pattern − lipid areas (red diamond) & myxoid regions (black star).
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eoplasms. Pathologic lymph node enlargement is commonly the
esult of metastatic spread from gastric or esophageal carcinoma or
ccasionally tuberculosis. Primary tumors of the lesser sac are rare
nd include benign tumors (lymphangioma, neurogenic tumor, ter-
toma) and malignant neoplasms (liposarcoma,GIST). Most tumors
nvolving the lesser sac represent secondary spread from intrinsic
umors of the stomach, liver or pancreas [4].
Primary lesser sac liposarcoma is scarcely reported though
etroperitoneal liposarcoma is a common tumor [3]. Liposarco-
as  are tumors of predominately adult men  primarily affecting thet) & Vimentin (right) positivity.
extremities followed by the retroperitonium. Liposarcoma occurs
in 3 main histomorphological forms each with unique biological
behavior, a well-differentiated, myxoid/or round cell and pleo-
morphic types. Some tumors have a combination of morphologic
types and are classiﬁed as combined or mixed-type liposarco-
mas. The anatomical distribution of liposarcoma is related to the
histologic type with well differentiated, myxoid/round-cell liposar-
comas and pleomorphic variants having a striking predilection
for the limbs,while dedifferentiated liposarcoma occurs predom-
inantly in the retroperitoneum. The risk of distant metastasis and
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urvival are inﬂuenced by histological type with well differenti-
ted, myxoid variants with a better outcome than pleomorphic and
ound cell types [1,2].
Myxoid liposarcoma accounts for approximately 40% of all
iposarcomas and usually prefers deep extremity soft tissues (66%)
ut rarely may  involve retroperitonium or subcutaneous tissue.
istological features include paucicellular myxoid stroma, arboris-
ng capillary network (chicken wire vessels), a bimorphic cell
opulation of signet ring lipoblast and uniform round cells rep-
esenting primitive non lipogenic mesenchymal cells. Occational
icrocyst enclosing eosinophil material may  be present. Lesions
ith a greater than 5% of round cell population have 5 year survival
ate of 50% and are deemed high grade while pure myxoid lesions
nd low grade lesions have a 90% 5 year survival [5].
Cytogenetically a speciﬁc translocation t(12;16) (q13-14;p11)
s found in about 90% of myxoid liposarcomas, including tumors
ith a mixture of myxoid and round cell components. In one-third
f the cases this translocation is the sole cytogenetic anomaly,
he other secondary aberration, trisomy 8 is seen in 6–8% of the
ases. An alternative unbalanced translocation t(12;22)(q13;q12)
as been identiﬁed in about 5% of the tumors [6]. The molecular
enetic consequences of the t(12;16) is the formation of a fusion
ranscrpt involving FUS in 16p11 and CHOP in 12q13. The role of
he encoding chimeric protein in pathogenesis or tumor biology
emains unknown [7]. This cytogenetic alteration is highly speciﬁc
or myxoid liposarcoma and its detection by FISH/RT- PCR has been
roposed to conﬁrm diagnosis when routine histology is inconclu-
ive [8].
Primary lesser sac tumors are often misdiagnosed clinically as
rising from the retroperitonium and radiographic imaging is the
ey to diagnosis. Imaging with USG is usually non diagnostic due
o superimposed bowel gas. CT scan is the imaging modality of
hoice with MRI  adding modest additional information. It permits
etection of anatomical origin of the tumor, offers a cue about his-
ology,assessment of operability and metastatic spread [9]. Speciﬁc
igns like the beak sign,embedded organ sign and the Phantom
rgan sign may  aid to differentiate from primary retroperitonieal
esions [9]. A CT imaging guided treatment policy obviating the
equirement for open biopsy has been suggested [10].
Myxoid liposarcomas are unique in that they tend to metasta-
ize to unusual soft tissue and bone locations with synchronous
r metachronous deposits in retroperitonium and axilla even in
he absence of pulmonary metastasis. Surgery is the treatment of
hoice. Adverse prognostic factors for local recurrence and survival
emain undeﬁned [5]. These tumors in contrast to other soft tissue
arcomas exhibit extraordinary high response to radiotherapy and
ubstantial sensitivity to trabectedin and ifosfamide chemother-
py [5]. In the series by wang et al. the risk of local recurrence
fter neoadjuvant or adjuvant radiotherapy was 8% at 5 years [11].
uadaganolo et al. from the MD Anderson Cancer Center demon-
trated a local recurrence of 3% in 127 patients treated with surgery
nd neoadjuvant and/or adjuvant radiotherapy [12]. The strongest
rgument for the effect of radiotherapy providing local control
omes from the large Canadian multicenter study consisting of 415
ases, in which the addition of radiotherapy signiﬁcantly prevented
ocal relapse (18% vs. 4%) and also reduced by sevenfold the 5-
ear local recurrence rate in patients with positive margins [13].
hemotherapy sensitivity of myxoid liposarcomas has been con-
rmed retrospectively by several authors (katz et al., patel et al.
nd Grosso et al.) and prospectively by Gronchi et al. in a phase II
rial [14–17]. The response rate as assessed by choi criteria varied
etween 43 and 86% in these studies with none reporting progres-
ion while on chemotherapy [17]. However the role of adjuvant
herapy for abdominal myxoid liposarcoma is unclear due to rarity
f these tumors at these sites.
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4. Conclusion
Primary lesser sac liposarcomas are rare neoplasms. The myxoid
variant is unique for its peculiar biological behavior, in its sen-
sitivity to chemotherapy and radiotherapy and for the presence
of speciﬁc cytogenetic marker. Caution is adviced regarding the
use of adjuvant therapy for abdominal myxoid liposarcomas as all
available data is derived from experience with extremity tumors.
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